Clinical Trials Browser

Phase 1/2 × OTHER × polatuzumab vedotin × Clear all

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06040320 2025-10-28

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin

NCT04914741 2024-08-12

COALITION

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse